Neurogene Inc’s filing revealed that its 10% Owner Samsara BioCapital GP, LLC acquired Company’s shares for reported $1.26 million on Nov 26 ’24. In the deal valued at $25.83 per share,48,770 shares were bought. As a result of this transaction, Samsara BioCapital GP, LLC now holds 1,717,127 shares worth roughly $28.5 million.
Then, Cvijic Christine Mikail bought 24,000 shares, generating $491,400 in total proceeds. Upon buying the shares at $20.48, the President and CFO now owns 76,844 shares.
Before that, McMinn Rachel bought 47,500 shares. Neurogene Inc shares valued at $969,000 were divested by the Chief Executive Officer at a price of $20.40 per share. As a result of the transaction, McMinn Rachel now holds 1,297,859 shares, worth roughly $21.54 million.
BMO Capital Markets initiated its Neurogene Inc [NGNE] rating to an Outperform in a research note published on June 27, 2024; the price target was $65. A number of analysts have revised their coverage, including Robert W. Baird’s analysts, who began to cover the stock in mid June with a ‘”an Outperform”‘ rating. Leerink Partners began covering NGNE with “an Outperform” recommendation on April 29, 2024. William Blair started covering the stock on March 21, 2024. It rated NGNE as “an Outperform”.
Price Performance Review of NGNE
On Friday, Neurogene Inc [NASDAQ:NGNE] saw its stock fall -5.84% to $16.60. Over the last five days, the stock has lost -15.22%. Neurogene Inc shares have fallen nearly -27.38% since the year began. Nevertheless, the stocks have fallen -44.96% over the past one year. While a 52-week high of $74.49 was reached on 01/06/25, a 52-week low of $14.44 was recorded on 01/17/25. SMA at 50 days reached $27.69, while 200 days put it at $36.08.
Levels Of Support And Resistance For NGNE Stock
The 24-hour chart illustrates a support level at 15.91, which if violated will result in even more drops to 15.22. On the upside, there is a resistance level at 17.52. A further resistance level may holdings at 18.43. The Relative Strength Index (RSI) on the 14-day chart is 29.73, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -3.11, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 94.71%. Stochastics %K at 6.56% indicates the stock is a buying.
How much short interest is there in Neurogene Inc?
A steep rise in short interest was recorded in Neurogene Inc stocks on 2024-10-31, dropping by -0.98 million shares to a total of 0.91 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 1.9 million shares. There was a decline of -107.49%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on January 08, 2024 when H.C. Wainwright began covering the stock and recommended ‘”a Buy”‘ rating along with a $45 price target.
